Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease

Medicine and Dentistry

• Patient 90%
• Surgery 36%
• Diseases 27%
• Induction Chemotherapy 27%
• Survival Rate 27%
• Toxicity 27%
• Overall Survival 18%
• Mucositis 18%
• Head and Neck Cancer 18%
• Chemoradiotherapy 18%
• Second Cancer 18%
• Follow up 9%
• Recurrent Disease 9%
• Progression Free Survival 9%
• Hydroxyurea 9%
• Fluorouracil 9%
• Disease Exacerbation 9%
• Treatment Duration 9%
• Primary Tumor 9%
• Long Term Survival 9%
• Bone Marrow Suppression 9%
• Cisplatin 9%
• Local Therapy 9%
• Folinic Acid 9%
• Interferon Alfa 2b 9%
• Life 9%
• Inpatient 9%
• Organ 9%

INIS

• patients 100%
• surgery 36%
• diseases 36%
• toxicity 27%
• induction 27%
• chemotherapy 27%
• cancer 18%
• malignancies 18%
• combined therapy 18%
• radiations 9%
• tumors 9%
• therapy 9%
• risks 9%
• organs 9%
• modifications 9%
• control 9%
• failures 9%
• death 9%
• radiation doses 9%
• interferon 9%
• hydroxyurea 9%
• fluorouracils 9%
• leucovorin 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Radiation 36%
• Diseases 27%
• Toxicity 27%
• Survival Rate 27%
• Overall Survival 18%
• Mucosa Inflammation 18%
• Head and Neck Cancer 18%
• Second Cancer 18%
• Hydroxycarbamide 9%
• Fluorouracil 9%
• Disease Exacerbation 9%
• Progression Free Survival 9%
• Primary Tumor 9%
• Recurrent Disease 9%
• Bone Marrow Suppression 9%
• Cisplatin 9%
• Long Term Survival 9%
• Folinic Acid 9%
• Alpha2b Interferon 9%
• Death 9%